Nov 01 2017
MONTEVIDEO, Uruguay—BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that it has launched ABRAXANE / ABRAXUS (nab-paclitaxel) in Brazil and Mexico.
Early this year, GBT had received exclusive rights from Celgene Corporation to promote, market, sell and distribute the products in the before mentioned territories.
During the month of October, several launch events were organized impacting an approximate 500 oncologists specialized in the treatment of pancreatic and breast cancers. During these scientific meetings, local and international experts discussed on the unmet medical needs of these conditions, evidence based-treatment guidelines and specially, on the profile and role of novel nab-paclitaxel in the medical practice.
GBT is honored to bring new hope to thousands of pancreatic cancer patients in Brazil and Mexico, a devastating disease with such high unmet medical needs.